참고문헌 (25)

1. 1 Lipsky PE van der Heijde DM St Clair EW Furst DE Breedveld FC Kalden JR Smolen JS Weisman M Emery P Feldmann M Harriman GR Maini RN Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group N Engl J Med 2000 343 1594 1602 11096166 

   상세보기

2. 2 Ledingham J Deighton C Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001) Rheumatology (Oxford) 2005 44 157 163 15637039 

3. 3 Keat A Barkham N Bhalla A Gaffney K Marzo-Ortega H Paul S Rogers F Somerville M Sturrock R Wordsworth P BSR guidelines for prescribing TNF-α blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology Rheumatology (Oxford) 2005 44 939 947 15901904 

4. 4 Braun J Davis J Dougados M Sieper J van der Linden S van der Heijde D First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis Ann Rheum Dis 2006 65 316 320 16096329 

   상세보기

5. 5 Hochberg MC Lebwohl MG Plevy SE Hobbs KF Yocum DE The benefit/risk profile of TNF-blocking agents: findings of a consensus panel Semin Arthritis Rheum 2005 34 819 836 15942917 

   상세보기

6. 6 Mutlu GM Mutlu EA Bellmeyer A Rubinstein I Pulmonary adverse events of anti-tumor necrosis factor-alpha antibody therapy Am J Med 2006 119 639 646 16887405 

7. 7 Gardam MA Keystone EC Menzies R Manners S Skamene E Long R Vinh DC Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management Lancet Infect Dis 2003 3 148 155 12614731 

   상세보기

8. 8 Keane J Gershon S Wise RP Mirabile-Levens E Kasznica J Schwieterman WD Siegel JN Braun MM Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent N Engl J Med 2001 345 1098 1104 11596589 

   상세보기

9. 9 American Thoracic Society Diagnostic standards and classification of tuberculosis in adults and children Am J Respir Crit Care Med 2000 161 1376 1395 10764337 

10. 10 Centers for Disease Control and Prevention (CDC); American Thoracic Society Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003 MMWR Morb Mortal Wkly Rep 2003 52 735 739 12904741 

11. 11 British Thoracic Society Standards of Care Committee BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment Thorax 2005 60 800 805 16055611 

    상세보기

12. 12 Korea Food and Drug Administration Guideline for diagnosis and treatment of latent tuberculosis infection in patients treated with TNF blockers 2004 

13. 13 Bai GH Park YK Choi YW Bai JI Kim HJ Chang CL Lee JK Kim SJ Trend of anti-tuberculosis drug resistance in Korea, 1994-2004 Int J Tuberc Lung Dis 2007 11 571 576 17439684 

14. 14 Arnett FC Edworthy SM Bloch DA McShane DJ Fries JF Cooper NS Healey LA Kaplan SR Liang MH Luthra HS Medsger TA Jr Mitchell DM Neustadt DH Pinals RS Schaller JG Sharp JT Wilder RL Hunder GG The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 1988 31 315 324 3358796 

15. 15 van der Linden S Valkenburg HA Cats A Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria Arthritis Rheum 1984 27 361 368 6231933 

16. 16 Sokal JE Measurement of delayed skin-test responses N Engl J Med 1975 293 501 502 1152865 

17. 17 Lee BH Koh WJ Choi MS Suh GY Chung MP Kim H Kwon OJ Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy Chest 2005 127 1304 1311 15821209 

    상세보기

18. 18 Sichletidis L Settas L Spyratos D Chloros D Patakas D Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis Int J Tuberc Lung Dis 2006 10 1127 1132 17044206 

19. 19 Nizam S Emery P Attenuated response to purified protein derivative in patients with rheumatoid arthritis Ann Rheum Dis 2006 65 980 16769792 

    상세보기

20. 20 Emery P Panayi G Symmons D Brown G Mechanisms of depressed delayed-type hypersensitivity in rheumatoid arthritis: the role of protein energy malnutrition Ann Rheum Dis 1984 43 430 434 6430250 

    상세보기

21. 21 Ponce de Leon D Acevedo-Vasquez E Sanchez-Torres A Cucho M Alfaro J Perich R Pastor C Harrison J Sanchez-Schwartz C Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis Ann Rheum Dis 2005 64 1360 1361 16100342 

    상세보기

22. 22 Wang L Turner MO Elwood RK Schulzer M FitzGerald JM A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements Thorax 2002 57 804 809 12200526 

23. 23 Kang YA Lee HW Yoon HI Cho B Han SK Shim YS Yim JJ Discrepancy between the tuberculin skin test and the whole-blood interferon γ assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country JAMA 2005 293 2756 2761 15941805 

24. 24 Lee JY Choi HJ Park IN Hong SB Oh YM Lim CM Lee SD Koh Y Kim WS Kim DS Kim WD Shim TS Comparison of two commercial interferon-γ assays for diagnosing Mycobacterium tuberculosis infection Eur Respir J 2006 28 24 30 16611658 

25. 25 Ena J Valls V Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis Clin Infect Dis 2005 40 670 676 15714411 

    상세보기

활용도 Top5 논문

더보기

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.